Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 plus PD-1 inhibitor as first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma
ChiCTR2600130919Phase 2Not yet recruiting
- Sponsor
- Guangzhou Panyu District Central Hospital
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Guangzhou Panyu District Central Hospital. Primary endpoint: Objective response rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600130919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130919.